Company Name True North Therapeutics
Mailing Address 951 Gateway Blvd South San Francisco, CA 94080
Company Description True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The company’s lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis.
Proceeds Purposes The Series A financing will be used to advance its lead drug candidate TNT009, a first-in-class monoclonal antibody that selectively inhibits a target of the Classical Complement pathway, into clinical trials.